Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib

Table 3 Univariate and multivariate analysis of the clinical parameters for the prediction of overall survival

Parameter	n	Univariate analysis		Multivariate analysis
		HR (95%CI)	P value	HR (95%CI)	P value
Sex
Woman	33	1
Man	49	1.26 (0.73-2.17)	0.418
Age (yr)
≥ 65	41	1
< 65	41	1.27 (0.75-2.17)	0.379
Staging
Locally advanced	14	1		1
Metastatic	68	2.87 (1.20-6.83)	0.017	2.10 (0.85-5.18)	0.108
ECOG performance status score
0-1	70	1		1
2	12	2.96 (1.49-5.89)	0.002	2.94 (1.42-6.08)	0.004
CA19-9 (IU/mL)
< 1000	48	1
≥ 1000	34	1.45 (0.79-2.66)	0.224
CEA (ng/mL)
< 5	46	1
≥ 5	29	1.67 (0.90-3.10)	0.107
NLR
≤ 5	62	1		1
> 5	20	2.61 (1.29-5.27)	0.008	2.76 (1.33-5.75)	0.007
PLR
≤ 150	46	1
> 150	36	1.43 (0.79-2.60)	0.24
CRP/albumin
≤ 0.5	42	1		1
> 0.5	40	2.13 (1.19-3.81)	0.011	1.60 (0.84-3.04)	0.151

ECOG: Eastern Cooperative Oncology Group; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; CRP: C-reactive protein; HR: Hazard ratio.